Catalogo dei prodotti della ricerca

SCALZULLI, EMILIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.031
EU - Europa 584
AS - Asia 505
SA - Sud America 10
AF - Africa 8
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.141
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.011
IT - Italia 341
SG - Singapore 284
CN - Cina 82
SE - Svezia 57
IN - India 44
TH - Thailandia 32
JP - Giappone 30
BG - Bulgaria 26
GB - Regno Unito 22
CA - Canada 20
FI - Finlandia 19
DE - Germania 18
RU - Federazione Russa 14
BE - Belgio 13
NL - Olanda 13
TR - Turchia 11
RO - Romania 10
IE - Irlanda 6
PL - Polonia 5
UA - Ucraina 5
CO - Colombia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
ES - Italia 4
KR - Corea 4
TG - Togo 4
AT - Austria 3
TW - Taiwan 3
AR - Argentina 2
AU - Australia 2
BD - Bangladesh 2
CH - Svizzera 2
ET - Etiopia 2
FR - Francia 2
HK - Hong Kong 2
HR - Croazia 2
ID - Indonesia 2
IS - Islanda 2
LT - Lituania 2
LV - Lettonia 2
MK - Macedonia 2
PE - Perù 2
PK - Pakistan 2
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BR - Brasile 1
CL - Cile 1
DZ - Algeria 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
PH - Filippine 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 2.141
Salva come PNG Salva come JPEG
Città #
Singapore 228
Rome 119
Fairfield 107
Santa Clara 105
Chandler 91
Ashburn 70
Woodbridge 43
Houston 42
Wilmington 39
Seattle 38
Bangkok 32
Princeton 30
Cambridge 28
Sofia 26
Tokyo 19
Milan 18
Millbury 18
New York 18
Bologna 14
Toronto 14
Brussels 13
Chicago 12
San Diego 11
Andover 9
Ann Arbor 9
Dearborn 9
Plano 9
Florence 8
Helsinki 8
Istanbul 8
Boardman 6
Boston 6
Dublin 6
Fiesole 6
Genova 6
Lappeenranta 6
Maitland 6
Amsterdam 5
Beijing 5
Norwalk 5
Ottawa 5
San Donato Milanese 5
Springfield 5
Stockholm 5
Bogotá 4
Bremen 4
Falkenstein 4
Frankfurt am Main 4
Lawrence 4
Lomé 4
London 4
Mapo-gu 4
San Paolo di Civitate 4
Tarquinia 4
Trento 4
Valenza 4
Warsaw 4
Arezzo 3
Arroyo de la Encomienda 3
Bühl 3
Copenhagen 3
Craigavon 3
Dallas 3
Genoa 3
Guangzhou 3
Lanciano 3
Los Angeles 3
Moscow 3
Nanjing 3
Prineville 3
Serra Riccò 3
Vantaa 3
Brescia 2
Brno 2
Buenos Aires 2
Caserta 2
Cincinnati 2
Cluj-Napoca 2
Conroe 2
Des Moines 2
Dhaka 2
Edinburgh 2
Fort Worth 2
Fremont 2
Fulham 2
Gablitz 2
Givoletto 2
Gonder 2
Groningen 2
Hong Kong 2
Iasi 2
Jakarta 2
Keelung 2
Kyoto 2
Lima 2
Modena 2
Montale 2
Montemiletto 2
Monza 2
Naples 2
Totale 1.425
Salva come PNG Salva come JPEG
Nome #
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab 71
The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing? 68
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors 63
PROPENSITY SCORE MATCHING ANALYSIS COMPARING ASCIMINIB VERSUS PONATINIB FOR ITS TREATMENT OUTOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS 62
Strongyloides stercoralis infection in allogeneic stem cell transplant: a case report and review of the literature. 58
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia 57
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients 55
null 54
null 51
null 50
null 46
A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms 44
Therapeutic strategies in low and high-risk MDS: What does the future have to offer? 44
Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants 43
null 42
null 41
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation 39
null 38
Case Report: Infectious prophylaxis in hematological malignancies 37
Incidence and outcome of infections after unrelated cord blood transplantation in patients with hematological malignancies: a long-term single center experience 37
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases 36
null 36
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort 32
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION 30
null 28
null 27
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice 27
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia. is it time to introduce it in the clinical practice? 27
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events 26
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols 26
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 25
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib 24
The advantages and risks of ruxolitinib for the treatment of polycythemia vera 24
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience 24
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms. a collaborative retrospective study by pH-negative MPN latial group 23
null 23
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort 23
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice 22
null 22
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report 21
REVISED “IRR6” MODEL IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB 21
Asciminib in chronic myeloid leukemia 20
CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB 20
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients 20
Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols 19
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors 19
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab 19
null 19
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions 19
Myelodysplastic syndromes with isolated 20q deletion: a new clinical-biological entity? 19
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 18
. Myeloma; living better and living longer - a look at the advances. 17
null 17
Incidence of Clinically Significant (<= 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib 16
Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters 16
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up 16
null 16
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds 15
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia 15
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 15
Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib 14
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents 14
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice 14
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience 14
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care 14
Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort 13
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 13
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life 13
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life 13
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia 13
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance 12
MUTANT MYELOID GENE CATEGORY MAY PREDICT POOR RESPONSE TO JAK INHIBITORS IN PATIENTS WITH MYELOFIBROSIS 12
Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study 12
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols 12
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study 11
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. ACampus CMLstudy 11
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 11
null 11
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 11
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up 11
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications 10
null 10
null 10
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 10
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia 9
The advantages and risks of ruxolitinib for the treatment of polycythemia vera 9
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety 9
null 9
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A ``Campus CML{''} Study 9
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group 8
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 8
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents 8
Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice 8
Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases 8
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia 8
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation 7
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors 7
null 6
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life 6
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors 6
Totale 2.296
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.776
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020131 0 0 0 0 0 29 24 19 16 14 8 21
2020/2021162 6 17 3 6 9 58 9 11 6 5 15 17
2021/2022300 9 1 12 15 47 17 5 19 39 27 70 39
2022/2023312 61 19 9 31 46 36 15 25 37 1 25 7
2023/2024532 51 57 23 70 52 52 14 25 10 50 50 78
2024/2025789 52 149 65 266 151 106 0 0 0 0 0 0
Totale 2.358